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CONCLUSIONS: The FSS scale is an instrument reliable and valid to measure mus-
cular fatigue in Brazilian patients with myopathy.
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A MIXED-EFFECTS PIECEWISE LINEAR MODEL OF THE RATE OF LUNG
FUNCTION DECLINE BEFORE AND AFTER THE CLINICAL USE OF DORNASE ALFA
IN AN OBSERVATIONAL STUDY OF CYSTIC FIBROSIS
Pasta DJ, Millar SJ, Rasouliyan L
ICON Late Phase & Outcomes Research, San Francisco, CA, USA
OBJECTIVES: To evaluate lung function decline before and after the initiation of
dornase alfa (DA) through a multivariable mixed-effects piecewise linear model
using data from the Epidemiologic Study of Cystic Fibrosis (ESCF). METHODS: Pa-
tients aged 8-38 years enrolled in ESCF for 2 or more years prior to initial treatment
with DA were selected if they remained on treatment for at least 2 years. A com-
parator group included cystic fibrosis patients not yet reported to have received DA.
FEV1 percent predicted (pp) was analyzed before and after an index measurement
within 30 days of either DA initiation (DA group) or an encounter within 1 year
following the 8th or subsequent even-numbered birthday (comparator group). For
each patient, we fit a regression line to FEV1 pp separately for the pre-index and
post-index periods (both 2 years in duration) using a mixed-effects piecewise linear
model adjusted for age, gender, pulmonary exacerbations, respiratory therapies,
and nutritional supplements. Patients were categorized by age group or by age-
adjusted deciles of the index FEV1 pp. RESULTS: The DA group (n2,230) had a
lower FEV1 pp at index and a more rapid decline during the pre-index period. There
was an acute improvement in FEV1 pp (change in intercept) associated with the
initiation of DA therapy. Furthermore, the mean rate of FEV1 pp decline was more
attenuated for the DA group than for the comparator group (n5,970) across age
groups and deciles. CONCLUSIONS: The use of DA for a 2-year period is associated
with both an acute improvement in FEV1 pp (previously shown in clinical trials)
and a reduction in the rate of FEV1 pp decline (shown for the first time). These
results demonstrate the value of using mixed-effects piecewise linear models in
observational studies to evaluate the effect of instituting a therapy on both the
slope and intercept of a continuous outcome.
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SOCIAL ECONOMIC BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH RARE DISEASES IN EUROPE (BURQOL-RD PROJECT). METHODS
OF SELECTION OF 10 DISEASES FOR A EUROPEAN SURVEY
Linertová R1, López-Bastida J2
1Fundación Canaria de Investigación y Salud (FUNCIS), Las Palmas de Gran Canaria, Spain,
2Universidad de Castilla - La Mancha; Servicio de Evaluación del Servicio Canario de la Salud,
Santa Cruz de Tenerife, Spain
OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model
capable of quantifying the socio-economic burden and Health-Related Quality of
Life (HRQOL) for patients with rare diseases (RD) and their caregivers in Europe. We
described the methodology used to select a set of 10 RD to be approached in a pilot
study. METHODS: BURQOL-RD project counts with 20 partners, from 8 European
countries: Spain, UK, France, Germany, Sweden, Italy, Hungary and Bulgaria. A
two-round Delphi process was used to generate consensus in the selection of the 10
RD among the project participants. The wide variability and dispersion of the re-
sponses received in the two Delphi rounds of prioritization suggested that an ad-
ditional procedure should be implemented to improve the representativeness of
selected diseases. A Lewis Carroll’s trilateral diagram was applied based on three
determinants. RESULTS: The two rounds of Delphi panel yielded into a prioritised
list, to which the Carroll diagram was applied, taking into account three determi-
nants: prevalence, availability of effective treatment and need for carer. The final
set of RD was obtained to be targeted in the pilot study of BURQOL-RD: Cystic
Fibrosis, Prader-Willi Syndrome, Haemophilia, Duchenne Muscular Dystrophy,
Epidermolysis Bullosa, Fragile X Syndrome, Sclerodermia, Mucopolysaccharidosis,
Juvenile Idiopathic Arthritis and Histiocytosis. CONCLUSIONS: This methodology
permitted to obtain an equilibrated set of RD for the pilot study of BURQOL-RD
project. The model that will be generated will not only be suitable to apply in a wide
range of RD but it will also be sufficiently flexible to identify and adapt to the
challenges faced by the different health and social care systems of EU member
states.
Urinary/Kidney Disorders – Clinical Outcomes Studies
PUK1
BELATACEPT VERSUS TACROLIMUS: RESULTS OF AN INDIRECT ANALYSIS
FROM A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE THERAPIES FOR
KIDNEY TRANSPLANT RECIPIENTS
Sidhu M1, Odeyemi AO2, Hart WM2, Dada BR2
1Astellas Pharma Europe, Staines, UK, 2EcoStat Consulting UK Ltd, Bow, London, UK
OBJECTIVES: To systematically identify and summarise the evidence of renal
transplant outcomes, toxicity and adverse effects in order to determine the most
effective options. In particular, comparing tacrolimus, the cornerstone of renal
transplantation therapy, with newer therapies that have been introduced since
2003.METHODS:An electronic literature search of MEDLINE, Current Contents and
the Cochrane Library databases was conducted, plus manual reference checks of
all articles involving controlled trials of kidney transplants and immunosuppres-
sive therapy between 2003 and July 2010. Studies were assessed for eligibility and
quality by two reviewers who extracted data independently. Studies were classified
according to CNI avoidance or reduction, steroid avoidance, and induction thera-
pies. Results were expressed as risk ratio (RR) with 95% confidence intervals (CI).
Where necessary, indirect comparison techniques were used to compare different
forms of tacrolimus with belatacept. RESULTS: Thirty-five studies from an initial
list of 2895 citations were included in the analysis. Results show CNI avoidance
leads to higher incidence of acute rejection (RR 2.52, 95% CI 1.11–5.75), which is a
known predictor for graft loss, but reduced chronic allograft nephropathy. Tacroli-
mus produces better rejection prophylaxis compared with ciclosporin (RR 0.38, 95%
CI 0.21–0.70), and ciclosporin produces lower acute rejection compared with be-
latacept (RR 0.32, 95% CI 0.19–0.55). Indirect analysis shows that tacrolimus is
superior to belatacept in acute rejection prophylaxis (RR 0.18, 95% CI 0.08–0.39), but
leads to more cases of a decrease in glomerular filtration rate (GFR) (RR 1.37, 95% CI
0.92–2.03); however, the long-term impact of a reduction in GFR in the context of a
CNI-free regimen is not clear at present. CONCLUSIONS: Direct and indirect com-
parisons demonstrate that CNIs, and in particular tacrolimus, remain superior
even against more recent compounds for preventing acute rejection. However,
more research needs to be done to find the optimum combination of therapies.
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COMPARATIVE EFFECTIVENESS OF INVESTIGATIONAL COMPOUND
FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN
CHRONIC KIDNEY DISEASE: SYSTEMATIC REVIEW AND MIXED TREATMENT
COMPARISON
Stradwick S1, Hartmann J2, Morgan A3, Freemantle N4
1BresMed Health Solutions, Sheffield, South Yorkshire, UK, 2Takeda Global Research &
Development Centre (Europe) Ltd, London, City of Westmins, UK, 3Sheffield University, Sheffield,
South Yorkshire, UK, 4University College London, London, Hampstead, UK
OBJECTIVES: To evaluate the comparative effectiveness of investigational com-
pound ferumoxytol for the treatment of iron deficiency anaemia (IDA) associated
with chronic kidney disease (CKD) compared to alternative iron replacement ther-
apies (IRT). Primary interest was the improvement in haemoglobin (Hb) from base-
line levels.METHODS:A comprehensive systematic review was conducted to iden-
tify any randomised controlled trials investigating the efficacy of IRTs for the
treatment of IDA in CKD where efficacy is defined as Hb change from baseline and
IRTs included intravenous (IV) and oral treatments. Twelve electronic databases
were searched up to November 2010 (language unrestricted). Two reviewers inde-
pendently assessed each identified reference and conducted subsequent data ex-
traction. Method quality of each included trial was also independently assessed in
accordance with NICE guidelines. A standard meta-analysis comparing oral iron to
ferumoxytol was initially conducted, reflecting the trial programme. The full net-
work of evidence that included IV and oral iron therapies was synthesised using a
mixed treatment comparison (MTC). The random effects model showed ‘predicting
superiority’ to the fixed effects model and was thus utilised. Mean efficacy was
estimated through analysing standardised effect sizes of trials and back-trans-
forming data to Hb values via weighted average standard deviation. RESULTS:
Seventeen published trials and one unpublished clinical study provided the heter-
ogeneous trial base for MTC analysis. Ferumoxytol was significantly favoured
when compared to oral iron therapy by conventional meta-analysis (0.61; 95%
CI0.44,0.79; P value0.0001) which was supported by results from the MTC ef-
ficacy analysis (0.48; 95% CI1.24,2.2). Significant differences in efficacy were not
observed between ferumoxytol and any of the alternative IV iron therapies.
CONCLUSIONS: The results from the conventional meta-analysis showed that the
model favoured investigational compound ferumoxytol, in terms of increasing Hb,
in comparison to oral iron therapy and suggested a modelled equivalence to cur-
rently approved alternative IV iron treatments.
PUK3
SOURCES OF HETEROGENEITY AMONG OVERACTIVE BLADDER CLINICAL TRIAL
ESTIMATES OF TOLTERODINE AND FESOTERODINE REDUCTIONS OF URGENCY
URINARY INCONTINENCE EPISODES RELATIVE TO PLACEBO
Snedecor SJ
Pharmerit North America, LLC, Bethesda, MD, USA
OBJECTIVES: Explore potential sources of heterogeneity among estimates of tolt-
erodine (TOL) and fesoterodine (FESO) efficacy relative to placebo (PBO) in patients
with overactive bladder and urgency urinary incontinence (UUI) from randomized
clinical trials (RCTs) published from 2001 – 2010. METHODS: RCTs evaluating TOL
4mg, solifenacin 5mg and/or 10mg, or FESO 4mg or 8mg compared to PBO reporting
mean reduction of UUI episodes/d from baseline to endpoint were identified. Treat-
ment effects (treatment response minus PBO response) and PBO responses were
tested for heterogeneity using Cochran’s Q statistic. Where heterogeneity was
present, other study variables (baseline UUI, baseline micturitions, gender, age,
diary evaluation days, publication year, and study duration) were evaluated for
potential confounding using linear regression methods. RESULTS: Statistical het-
erogeneity was found among the 17 PBO responses (mean reduction of UUI) of the
included studies. PBO response increased with publication year, which accounted
for more than 27% of response variation. Publication year (p0.02), gender
(p0.003), and study duration (6-week vs. other) (p0.006) were significant predic-
tors of PBO response (adj. R20.6261). TOL and FESO 8mg treatment effect esti-
mates were also heterogeneous. Among the nine TOL trials, treatment responses
remained constant over publication year while PBO responses increased, resulting
in a net decline in TOL treatment effect (p0.0928). The majority of this decline was
explained by publication year and study duration (adj. R20.7703). The four FESO
8mg UUI responses also displayed a publication year-dependent decrease leading
to a decreasing treatment effect relative to PBO. However, this trend was almost
fully predictable by differential baseline UUI episodes (adj. R20.9721).
CONCLUSIONS: Publication year, gender, 6-week duration, and baseline UUI were
found to be significant predictors of PBO response or treatment effect. Additional
research should be done to understand why PBO response has increased over time
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and future trials should compare to real-world treatments wherever possible to
demonstrate clinically-meaningful differences.
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COMPARING PROJECTED OUTCOMES OF RENAL TRANSPLANT RECIPIENTS
BASED ON TRIAL ENDPOINT OF RENAL FUNCTION AND RECEIVING DIFFERENT
IMMUNOSUPPRESSIVE REGIMENS IN THE UNITED STATES
Levy A1, Briggs A2, Johnston K3, Schnitzler M4, LItalien GJ5, Yuan Y6, Kasiske B7
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OBJECTIVES: Enhancements in renal transplant have led to reduced rates of acute
rejection leading to a shift to kidney function as an accepted endpoint in efficacy
trials. Characterizing long-term benefits requires modeling to project long-term
outcomes of treatment based on kidney function. The goal of this study was to
project rates of graft failure and quality adjusted life years over the lifetimes of
hypothetical patients receiving belatacept (a recently-introduced selective co-
stimulation blocker), cyclosporine or tacrolimus. METHODS: We developed a sim-
ulation with two phases that integrated trial-based information with a long-term
four-state Markov model (functioning graft, graft failure on dialysis, functioning
re-graft, and death). In the first phase, three-year distributions of patients in four
estimated glomerular filtration rate (eGFR) categories (60, 45-59, 30-44 and 15-29,
with graft failure assumed at eGFR 15 mLs/min/1.73m2) were estimated using a
mixed treatment comparison of cyclosporine, belatacept, and tacrolimus. The
Markov phase was populated using transplant recipient data from the United
States Renal Data System (n34,130). Utilities for adjusting life-years were ob-
tained from a study of US renal transplant patients. RESULTS: Over a 20-year
modeled time-horizon for 1,000 hypothetical patients, belatacept was associated
with 551 graft failures,and 9.6 quality-adjusted life years. Relative to cyclosporine,
belatacept was associated with 0.9 additional quality-adjusted life years, and 56
fewer graft failures. Relative to tacrolimus, belatacept was associated with 0.9 ad-
ditional quality-adjusted life years, and 18 fewer graft failures. CONCLUSIONS:
This is the first long-term follow-up model of renal transplant patients to be based
on trial-based graft function endpoints and include all relevant comparators. This
long-term extrapolation of differences in kidney function observed at three years
shows clinically important differences between treatments. While validation of
these models will require long-term follow-up of patients, modeling based on renal
function may prove to be a useful method of projecting long-term outcomes.
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MIXED TREATMENT COMPARISONS OF IMMUNOSUPPRESSANTS FOLLOWING
RENAL TRANSPLANT
Thurston S1, Kalsekar A2, LItalien GJ3, Sennfält K4
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BACKGROUND: Belatacept is a first in-class co-stimulation blocker developed for
primary maintenance immunosuppression following renal transplantation. Data
is widely available comparing belatacept to cyclosporine, limited data is available
comparing it with other immunosuppressants. OBJECTIVES: Estimate belatacept’s
efficacy and safety relative to tacrolimus. METHODS: A systematic review was
conducted of randomised controlled trials (RCTs) published between January 1990
and September 2010. Data extraction captured study duration, quality, baseline
data, treatment and clinical outcomes. Efficacy and safety outcomes included glo-
merular filtration rate (GFR), graft- and patient-survival, and acute rejection (AR).
The data were analysed with fixed- and random-effects models. Linear models
with outcome of mean difference were applied for GFR because GFR (ml/min) is a
continuous measure, unlike the other variables which are dichotomous in nature.
Logistic models were used for these other outcomes (summary measure being odds
ratios). Sensitivity analyses (SAs) were conducted based on trial durations and
sub-populations.RESULTS:We identified twenty-six RCTs comparing cyclosporine
with tacrolimus, three RCTs comparing cyclosporine with belatacept, and no trials
comparing tacrolimus with belatacept. Most trials were 12 months in duration
(range: 6 to 60 months). MTC results using 36 month belatacept data suggested
benefits with belatacept on patient survival (OR0.62 95%CI: 0.31,1.24), and differ-
ence in GFR (8.50 ml/min/1.73 m2; 95% CI ( 4.22,20.44), versus tacrolimus, with AR
outcomes favouring tacrolimus (OR2.43; 95%CI 1.08,5.34). MTC results indicated
reduced graft-survival with belatacept at 36 months (OR1.18 95%CI: 0.51,2.85).
However, SAs using data at 12 months post-transplant demonstrated a benefit for
belatacept on graft-survival (OR0.89 95%CI: 0.36,2.16). Benefits on graft-survival
were also seen at 12 and 24 months in the standard-criteria donor population. SAs
on the other outcomes resulted in similar conclusions to those of the base case.
CONCLUSIONS: Belatacept showed improved renal function and benefits in graft-
and patient-survival in comparison to tacrolimus despite increased risks for AR.
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BPH PATIENTS TREATED WITH PHYTOTHERAPY IN PORTUGAL: RESULTS AT
SIX MONTHS
Perrin P1, Auges M2, Rahhali N2, Taieb C2
1Lyon Sud, Pierre Benite, France, 2PFSA, Boulogne Billancourt, France
OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract related to benign prostatic hypertrophy (BPH) using medical treat-
ment under actual conditions of use. METHODS: A pragmatic cohort of patients
treated medically, was followed up for 6 months, using validated questionnaires:
IPSS and MSF4. RESULTS: Fifty-one patients treated with Serenoa Repens (hexanic
extract) were evaluated, the mean age was 61.51 8.11 years, and on average the
diagnosis had been made 3.6 months previously.At 6 weeks, the IPSS was signifi-
cantly improved (p0.0001). This improvement in the IPSS score between 6 weeks
(10.155.36) and inclusion (13.766.03) was 3.6 points. An improvement was also
observed at 3 months. At 6 months, the p-value was also significant (p0.0001). The
improvement in the IPSS score between 6 months (6.903.46) and inclusion
(12.936.09) was 6 points.The MSF4 was unchanged. CONCLUSIONS: We observed
an improvement in the IPSS score from the sixth week; this statistical improve-
ment was confirmed by a significant clinical improvement in the sixth month.
Urinary/Kidney Disorders – Cost Studies
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3 YEARS FOLLOW UP OF THE PHARMACOTHERAPY COST OF PATIENTS WITH
KIDNEY TRANSPLANTATION IN BULGARIA
Georgieva SS1, Stoimenova A2, Petrova G3
1Aleksandrovska Hospital, Sofia, Bulgaria, 2Medical University Sofia, Faculty of Pharmacy, Sofia,
Bulgaria, 3Medical University, Faculty of Pharmacy, Sofia, Bulgaria
OBJECTIVES: To analyze the cost savings after the consecutive introduction of the
generic immunospressants Azathioprine, Mycophenolic acid and Ciclosporin for
patients with transplanted kidney in Bulgaria. METHODS: Prospective observa-
tional study of the pharmacotherapy cost of patients after kidney transplantation
during 36 months (Mar 2008 – February 2011) was performed; 528 patients switched
to at least one of the generic immunosupressors were followed. Patients were
classified in 3 periods – beginning, during and after the switch. It was also followed
the changes in the whole pharmacotherapy as an indicator for switch compliance.
Mean cost per patient and cost saving were calculated. RESULTS: A total of 433
patients were treated with combined immunosuppressive therapy containing at
least one of the 4 originators (Imuran, Myfortic, Cellcept, Sandimmune) through
the Period 1 and then consecutively they increase to 528. Per patient cost of therapy
with the observed medications differs among the age groups and among the peri-
ods with low cost for age group of up to 70 years old. The introduction of generic
Azathioprine in 2009 reduced the mean pharmacotherapy cost for all patients with
6% from 4814 - 4539 BGN (2461 - 2321EUR). At the same time the introduction of
generic mycophenolic acid‘s derivates and appearance of generic ciclosporin in
2010 reduced the mean pharmacotherapy cost of the observed patients more than
2 times (119%) from 4539 – 2076 BGN (2321 – 1061 EUR). Total reduction of the mean
pharmacotherapy cost (Period 1 vs. Period 3) was 132% from 4814 – 2076 BGN (2461
– 1061 EUR). No other changes in the pharmacotherapy were observed, as well as no
back transfer to originator products. CONCLUSIONS: The introduction of generic
immunosuppressors significantly decreased the mean cost of therapy and let to
high cost savings for the hospital budget without any additional changes in the
patients’ pharmacotherapy.
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CHRONIC KIDNEY DISEASE BURDENS PATIENTS, HEALTH CARE SYSTEMS, AND
EMPLOYERS
Davis K1, Sood V2, Hogue S1, Braun LA1, Copley-Merriman C3, Lieberman B2
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OBJECTIVES: To elucidate patient and economic burden associated with chronic
kidney disease (CKD) across countries. METHODS: A targeted literature review
using PubMed and desktop research was performed. Currency conversions were
adjusted to 2010. RESULTS: North American, European, and Asian studies were
identified; most reports were from the United States (US). Advanced CKD (stages
3-5) adversely affects outcomes. As patient-reported outcomes (PROs) deteriorate,
resource utilization (RU) and costs escalate. Across studies, patients with CKD
report cognitive impairment, dementia, sleep disturbance, and emotional and
physical dysfunction (PD), with PD being most pervasive. Compared with general
populations across countries, Health-related Quality of Life (HRQOL) and other
PROs decline in patients with CKD. Age, female gender, less education, lower in-
come, unemployment, limited exercise, and comorbid illness are predictors of re-
duced HRQOL. RU and costs to healthcare systems and employers increase with
CKD severity. Prior to (12-24 months) dialysis initiation, costs increase substan-
tially due to hospitalization. Annual US total cost per patient (c/p/p) with CKD
(stages 3-5) range from $6,026 (€4,927) to $30,398 (€24,855); annual Germany total
c/p/p (stages 1-4) is €3,581 ($4,379), compared to €1,272 ($1,555) in those without
CKD. The cost burden of CKD is rising. From 1993 to 2007, Medicare costs for pa-
tients with CKD increased by 5-fold. High healthcare costs (HC) and reduced
productivity due to CKD, burdens employers. For employees with CKD (US), HCs
range from $1,187 (€971) (stage 3) to $21,826 (€17,846) (stage 5) and work-hours
missed per week often exceeds 10. The impact of CKD on patient and economic
burden across countries is evident. CONCLUSIONS: Patient and economic burden
associated with CKD is considerable across countries. With disease progression
and kidney-function decline, unfavorable outcomes arise. As evidenced by the high
patient and economic burden of CKD, a large unmet need exists for new therapies
and employee CKD-management programs.
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COMPARATIVE COST ANALYSIS OF TREATMENT FOR RENAL ANEMIA WITH
METHOXY POLYETHYLENE-GLYCOL ERYTHROPOIETIN BETA (MIRCERA®)
VERSUS ERYTHROPOIETIN BETA (NEORECORMON®)
Medina Gómez JL
ISSSTE, Mexico City, Mexico, Mexico
OBJECTIVES: Evaluate if the use of Methoxy polyethylene-glycol erythropoietin
beta (MPG-beta) offers better health outcomes and costs with respect to erythro-
poietin beta multidose presentation (50,000 IU). METHODS: Analysis of incremen-
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